Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PCSK9
Biotech
Verve halts VERVE-101 enrollment, focuses on 2nd PCSK9 editor
The patient who had two grade 3 side effects after receiving VERVE-101 was asymptotic, and lab abnormalities resolved within days.
Max Bayer
Apr 2, 2024 7:00am
Merck bets big on oral PCSK9 inhibitor with phase 3 program
Aug 25, 2023 8:35am
FDA hands Verve list of demands for lifting gene editing hold
Dec 5, 2022 9:20am
AstraZeneca dumps drug despite hit in phase 2 cholesterol trial
Sep 23, 2022 5:23am
Vertex puts up $60M to partner on in vivo gene editing program
Jul 21, 2022 9:10am
Phase 3 hits tee Innovent up to rival Amgen and Sanofi in PCSK9
Feb 17, 2022 9:40am
